Latest Articles

Publication Date
How long does combined hormonal therapy suppress AMH levels in women with endometriomas? Results from an exploratory analysis of a clinical trial.

Lower Anti-Müllerian hormone (AMH) levels have been observed in women with ovarian endometriomas (OMA) undergoing combined hormonal contraceptive (CHC) therapy. However, the extent and timing of AMH recovery after CHC …

Published: Sept. 16, 2025, midnight
Severe endometriosis complicated by deep vein thrombosis and pulmonary embolism in the absence of hormone therapy: A case report and literature review.

To report a rare case of severe endometriosis complicated by deep vein thrombosis (DVT) and pulmonary embolism (PE) without hormone exposure, and review similar cases in the literature.

Published: Sept. 13, 2025, midnight
Understanding Endometriosis: A Broad Review of Its Causes, Management, and Impact.

Endometriosis is a complex gynecological condition affecting 10% of women globally, characterized by the growth of endometrial-like tissue outside the uterus, leading to chronic pelvic pain, infertility, reduced quality of …

Published: Sept. 12, 2025, midnight
Specialty Influences Postcancer Hormone Therapy Prescribing - Medscape

Specialty Influences Postcancer Hormone Therapy Prescribing Medscape

Published: Sept. 11, 2025, 1:07 p.m.
Impact of endometrioma management strategies on ovarian reserve over the follow-up period, a prospective longitudinal study.

The effects of current treatment options for endometrioma on ovarian reserve remain controversial. Recent advancements in surgical techniques may challenge the previously established evidence regarding the detrimental effects of surgery …

Published: Sept. 11, 2025, midnight
Neuropathic-like pain affects pain perception in patients with deep endometriosis: an observational study.

Endometriosis is a chronic, hormone-dependent disease affecting up to 10% of women of reproductive age, often associated with chronic pelvic pain (CPP). Neuropathic pain has been increasingly recognized as a …

Published: Sept. 10, 2025, midnight
Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States.

Endometriosis symptoms have multifaceted manifestations, and there are few approved nonsurgical treatment options. Gonadotropin-releasing hormone (GnRH) agonists/antagonists for endometriosis vary on efficacy, safety profile, and out-of-pocket (OOP) cost, among other …

Published: Sept. 7, 2025, midnight
The Impact of Nutrition on Endometriosis Complaints in Patients Using and Not Using Hormone Therapy.

Endometriosis is a chronic inflammatory disease marked by the presence of endometrial tissue outside the uterus. Main symptoms include pain in the sacrum, pelvis, and abdomen, occurring at various stages …

Published: Sept. 6, 2025, midnight
Clinical efficacy and safety of Chinese patent medicines combined with hormonal therapy for endometriosis after laparoscopic surgery: A Bayesian network meta-analysis.

Chinese patent medicines (CPMs), standardized herbal formulations widely used in clinical practice, combined with hormones have shown favorable therapeutic effects in the adjuvant treatment of endometriosis (EMS) after laparoscopic surgery. …

Published: Sept. 6, 2025, midnight
MIG-6 Plays a Critical Role as a PGR Mediator in Maintaining Epithelial and Stromal Cells for Uterine Receptivity.

Ovarian steroid hormones-estrogen and progesterone-play a central role in regulating epithelial-stromal interactions in the uterus. These interactions are critical for uterine function, including endometrial receptivity, implantation, and decidualization. These interactions …

Published: Sept. 5, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!